A Non-Interventional Study of Bosutinib in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)

Study identification

• EU PAS number:
  EUPAS5461
• Study ID:
  18483
• Official title and acronym:
  A Non-Interventional Study of Bosutinib in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  A Non-Interventional Study of Bosutinib in Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia (CML)
• Study status:
  Finalised

Research institutions and networks

Institutions

Pfizer

Multiple centres: 30 centers are involved in the study

Study timelines

Date when funding contract was signed

Planned:01/04/2014

Actual:28/10/2013

Study start date

Planned:01/05/2014

Actual:08/01/2014

Date of final study report

Planned:23/06/2015

Actual:23/06/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable